Swedish Orphan Biovitrum AB increased revenue by 27% in the second quarter on the back of demand for its rare disease therapy Orfadin for hereditary tyrosinaemia type 1. During the quarter, Sobi and its partner Biogen also received FDA approval for a new haemophilia A product.
